+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Scynexis Inc - logo

SCYNEXIS is a drug development company that develops and commercializes anti-infectives to address unmet therapeutic needs. Its lead product candidate, SCY-078, is a novel and structurally distinct triterpenoid glucan synthase inhibitor. SCY-078 is in Phase 2 clinical development as an oral and intravenous drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. Founded in 1999, the company is headquartered in Jersey City, New Jersey.

Hepatitis Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Hepatitis Drug Development Pipeline Review, 2018

  • Report
  • June 2018
  • 133 Pages
From
Allergic Bronchopulmonary Aspergillosis - Pipeline Insight, 2020 - Product Thumbnail Image

Allergic Bronchopulmonary Aspergillosis - Pipeline Insight, 2020

  • Drug Pipelines
  • February 2020
  • 106 pages
From
Hepatitis B - Pipeline Review, H2 2020 - Product Thumbnail Image

Hepatitis B - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 575 pages
From
Aspergillosis Disease - Global Clinical Trials Review, H2, 2020 - Product Thumbnail Image

Aspergillosis Disease - Global Clinical Trials Review, H2, 2020

  • Clinical Trials
  • December 2020
  • 205 pages
From
From
Aspergillosis Global Clinical Trials Review, H1, 2020 - Product Thumbnail Image

Aspergillosis Global Clinical Trials Review, H1, 2020

  • Clinical Trials
  • June 2020
  • 183 pages
From
From
From
From
Antifungals Global Market Report 2020 - Product Thumbnail Image

Antifungals Global Market Report 2020

  • Report
  • November 2019
  • 200 pages
From
From
From
Loading Indicator
adroll